Vistagen Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.54 Mil. Vistagen Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.72 Mil. Vistagen Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $123.29 Mil.
Vistagen Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.02.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Vistagen Therapeutics's Debt-to-Equity or its related term are showing as below:
VTGN'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.19 Med: 0.02 Max: 2.76
Current: 0.02
During the past 13 years, the highest Debt-to-Equity Ratio of Vistagen Therapeutics was 2.76. The lowest was -1.19. And the median was 0.02.
Vistagen Therapeutics Debt-to-Equity Historical Data
The historical data trend for Vistagen Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Vistagen Therapeutics Annual Data
|
|
Trend |
Mar14 |
Mar15 |
Mar16 |
Mar17 |
Mar18 |
Mar19 |
Mar20 |
Mar21 |
Mar22 |
Mar23 |
| Debt-to-Equity |
|
|
|
|
|
|
0.01 |
-0.71 |
0.04 |
0.05 |
0.23 |
|
Vistagen Therapeutics Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.15 |
0.23 |
0.48 |
0.07 |
0.02 |
Competitive Comparison
For the Biotechnology subindustry, Vistagen Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistagen Therapeutics Debt-to-Equity Distribution
For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Vistagen Therapeutics's Debt-to-Equity falls into.
Vistagen Therapeutics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Vistagen Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as
Vistagen Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistagen Therapeutics (Vistagen Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
343 Allerton Avenue, South San Francisco, CA, USA, 94080
Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. The company's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. The portfolio of the company includes PH94B, a novel neuroactive nasal spray; PH10, an odorless, fast-acting synthetic neurosteroid and AV-101, an oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR) which is the Company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy.
Executives
| Joshua S. Prince |
officer: Chief Operating Officer |
C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080 |
| Cynthia Lynn Anderson |
officer: CHIEF FINANCIAL OFFICER |
C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080 |
| Commodore Capital Lp |
10 percent owner |
444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022 |
| Jerry B Gin |
director |
343 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080 |
| Reid G. Adler |
officer: CHIEF LEGAL OFFICER |
C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94090 |
| Shawn Singh |
director, officer: CHIEF EXECUTIVE OFFICER |
C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080 |
| Venrock Healthcare Capital Partners Ii, L.p. |
10 percent owner |
7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018 |
| Vhcp Management Ii, Llc |
10 percent owner |
7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018 |
| Vhcp Management Eg, Llc |
10 percent owner |
3340 HILLVIEW AVENUE, PALO ALTO CA 94304 |
| Venrock Healthcare Capital Partners Eg, L.p. |
10 percent owner |
3340 HILLVIEW AVENUE, PALO ALTO CA 94304 |
| Vhcp Co-investment Holdings Iii, Llc |
10 percent owner |
7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018 |
| Bong Y Koh |
10 percent owner |
7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018 |
| Vhcp Co-investment Holdings Ii, Llc |
10 percent owner |
7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018 |
| Nimish P Shah |
10 percent owner |
7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018 |
| Venrock Healthcare Capital Partners Iii, L.p. |
10 percent owner |
530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036 |
Vistagen Therapeutics (Vistagen Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VTGN has been successfully added to your